Purification and characterization of OXA-23 from Acinetobacter baumannii

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 28, Issue 4, 2013, Pages 836-842

  Torol, Sinem ^a   Kasap, Murat ^a  

^a KOCAELI UNIVERSITY   (Turkey)

Author keywords

Acinetobacter spp.; Beta lactamase; Enzyme kinetics; OXA 23 modelling; OXA 23 purification

Indexed keywords

AMPICILLIN; BACTERIAL PROTEIN; CEFEPIME; CEFTAZIDIME; CLAVULANIC ACID; HYBRID PROTEIN; IMIPENEM; MALTOSE BINDING PROTEIN; MEROPENEM; NITROCEFIN; OXA 23 PROTEIN; PENICILLIN G; PIPERACILLIN; SULBACTAM; TAZOBACTAM; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ESCHERICHIA COLI; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN ISOLATION; PROTEIN PURIFICATION; PROTEIN STRUCTURE;

ACINETOBACTER BAUMANNII; BETA-LACTAMASES; CLAVULANIC ACID; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ESCHERICHIA COLI; KINETICS; MODELS, MOLECULAR; PENICILLANIC ACID; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; SULBACTAM; SURFACE PROPERTIES;

EID: 84880080419     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2012.689296     Document Type: Article

References (34)

1. Giamarellou H, Antoniadou A, Kanellakopoulou K. Acinetobacter baumannii: a universal threat to public health? Int J Antimicrob Agents 2008;32:106-119.
2. Walther-Rasmussen J, Høiby N. OXA-type carbapenemases. J Antimicrob Chemother 2006;57:373-383.
3. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 2006;12:826-836.
4. Brown S, Amyes S. OXA (beta)-lactamases in Acinetobacter: the story so far. J Antimicrob Chemother 2006;57:1-3.
5. Bonnet R, Marchandin H, Chanal C, Sirot D, Labia R, De Champs C et al. Chromosome-encoded class D beta-lactamase OXA-23 in Proteus mirabilis. Antimicrob Agents Chemother 2002;46:2004-2006.
6. Boo TW, Walsh F, Crowley B. First report of OXA-23 carbapenemase in clinical isolates of Acinetobacter species in the Irish Republic. J Antimicrob Chemother 2006;58:1101-1102.
7. Dalla-Costa LM, Coelho JM, Souza HA, Castro ME, Stier CJ, Bragagnolo KL et al. Outbreak of carbapenem-resistant Acinetobacter baumannii producing the OXA-23 enzyme in Curitiba, Brazil. J Clin Microbiol 2003;41:3403-3406.
8. Jeon BC, Jeong SH, Bae IK, Kwon SB, Lee K, Young D et al. Investigation of a nosocomial outbreak of imipenem-resistant Acinetobacter baumannii producing the OXA-23 beta-lactamase in korea. J Clin Microbiol 2005;43:2241-2245.
9. Naas T, Levy M, Hirschauer C, Marchandin H, Nordmann P. Outbreak of carbapenem-resistant Acinetobacter baumannii producing the carbapenemase OXA-23 in a tertiary care hospital of Papeete, French Polynesia. J Clin Microbiol 2005;43:4826-4829.
10. Turton JF, Kaufmann ME, Glover J, Coelho JM, Warner M, Pike R et al. Detection and typing of integrons in epidemic strains of Acinetobacter baumannii found in the United Kingdom. J Clin Microbiol 2005;43:3074-3082.
11. Donald HM, Scaife W, Amyes SG, Young HK. Sequence analysis of ARI-1, a novel OXA beta-lactamase, responsible for imipenem resistance in Acinetobacter baumannii 6B92. Antimicrob Agents Chemother 2000;44:196-199.
12. Meric M, Kasap M, Gacar G, Budak F, Dundar D, Kolayli F et al. Emergence and spread of carbapenem-resistant Acinetobacter baumannii in a tertiary care hospital in Turkey. FEMS Microbiol Lett 2008;282:214-218.
13. Segal H, Garny S, Elisha BG. Is IS(ABA-1) customized for Acinetobacter? FEMS Microbiol Lett 2005;243:425-429.
14. Sambrook J, Russell WD. (2001). Molecular cloning: a laboratory manual, 3rd ed. New York: Cold Spring Harbor Lab.
15. Kasap M, Torol S, Gacar G. Comparison of electrocompetencies of some commenly used laboratory strains of Eschericia coli. JABS 2007;2:19-22.
16. Giuliani F, Docquier JD, Riccio ML, Pagani L, Rossolini GM. OXA-46, a new class D beta-lactamase of narrow substrate specificity encoded by a blaVIM-1-containing integron from a Pseudomonas aeruginosa clinical isolate. Antimicrob Agents Chemother 2005;49:1973-1980.
17. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-685.
18. Santillana E, Beceiro A, Bou G, Romero A. Crystal structure of the carbapenemase OXA-24 reveals insights into the mechanism of carbapenem hydrolysis. Proc Natl Acad Sci USA 2007;104:5354-5359.
19. Jacobs DJ, Rader AJ, Kuhn LA, Thorpe MF. Protein flexibility predictions using graph theory. Proteins 2001;44:150-165.
20. Gacar GG, Midilli K, Kolayli F, Ergen K, Gundes S, Hosoglu S et al. Genetic and enzymatic properties of metallo-beta-lactamase VIM-5 from a clinical isolate of Enterobacter cloacae. Antimicrob Agents Chemother 2005;49:4400-4403.
21. Holland S, Dale JW. Improved purification and characterization of the OXA-2 beta-lactamase. Biochem J 1984;224:1009-1013.
22. Bouillenne F, Matagne A, Joris B, Frère JM. Technique for a rapid and efficient purification of the SHV-1 and PSE-2 beta-lactamases. J Chromatogr B Biomed Sci Appl 2000;737:261-265.
23. Jelsch C, Lenfant F, Masson JM, Samama JP. Beta-lactamase TEM1 of E. coli. Crystal structure determination at 2.5 A resolution. FEBS Lett 1992;299:135-142.
24. Kapust RB, Waugh DS. Escherichia coli maltose-binding protein is uncommonly effective at promoting the solubility of polypeptides to which it is fused. Protein Sci 1999;8:1668-1674.
25. Adikesavan NV, Mahmood SS, Stanley N, Xu Z, Wu N, Thibonnier M et al. A C-terminal segment of the V1R vasopressin receptor is unstructured in the crystal structure of its chimera with the maltose-binding protein. Acta Crystallogr Sect F Struct Biol Cryst Commun 2005;61:341-345.
26. Kobe B, Center RJ, Kemp BE, Poumbourios P. Crystal structure of human T cell leukemia virus type 1 gp21 ectodomain crystallized as a maltose-binding protein chimera reveals structural evolution of retroviral transmembrane proteins. Proc Natl Acad Sci USA 1999;96:4319-4324.
27. Liu Y, Manna A, Li R, Martin WE, Murphy RC, Cheung AL et al. Crystal structure of the SarR protein from Staphylococcus aureus. Proc Natl Acad Sci USA 2001;98:6877-6882.
28. Paetzel M, Danel F, de Castro L, Mosimann SC, Page MG, Strynadka NC. Crystal structure of the class D beta-lactamase OXA-10. Nat Struct Biol 2000;7:918-925.
29. Afzal-Shah M, Woodford N, Livermore DM. Characterization of OXA-25, OXA-26, and OXA-27, molecular class D beta-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 2001;45:583-588.
30. Héritier C, Poirel L, Aubert D, Nordmann P. Genetic and functional analysis of the chromosome-encoded carbapenem-hydrolyzing oxacillinase OXA-40 of Acinetobacter baumannii. Antimicrob Agents Chemother 2003;47:268-273.
31. Héritier C, Poirel L, Fournier PE, Claverie JM, Raoult D, Nordmann P. Characterization of the naturally occurring oxacillinase of Acinetobacter baumannii. Antimicrob Agents Chemother 2005;49:4174-4179.
32. Keith KE, Oyston PC, Crossett B, Fairweather NF, Titball RW, Walsh TR et al. Functional characterization of OXA-57, a class D betalactamase from Burkholderia pseudomallei. Antimicrob Agents Chemother 2005;49:1639-1641.
33. Bou G, Oliver A, Martínez-Beltrán J. OXA-24, a novel class D beta-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain. Antimicrob Agents Chemother 2000;44:1556-1561.
34. Girlich D, Naas T, Nordmann P. Biochemical characterization of the naturally occurring oxacillinase OXA-50 of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2004;48:2043-2048.